E4NA Stock Overview
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arovella Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.064 |
| 52 Week High | AU$0.12 |
| 52 Week Low | AU$0.021 |
| Beta | -0.64 |
| 1 Month Change | -9.93% |
| 3 Month Change | -11.19% |
| 1 Year Change | 49.41% |
| 3 Year Change | 252.78% |
| 5 Year Change | -15.33% |
| Change since IPO | -96.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| E4NA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.8% | 2.3% | 0.5% |
| 1Y | 49.4% | -28.6% | 1.3% |
Return vs Industry: E4NA exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: E4NA exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| E4NA volatility | |
|---|---|
| E4NA Average Weekly Movement | 15.4% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E4NA's share price has been volatile over the past 3 months.
Volatility Over Time: E4NA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Michael Baker | www.arovella.com |
Arovella Therapeutics Limited, a biotechnology company, focuses on the development of therapies for the treatment of cancer and conditions that affect the central nervous system in Australia and internationally. Its product pipeline includes ZolpiMist, an oral spray of zolpidem tartrate to treat insomnia, which is marketed under the brand name of Ambien or Stilnox; and invariant natural killer T (iNKT), a cell therapy platform to treat blood cancer. It has a collaborative research agreement with Imperial College London.
Arovella Therapeutics Limited Fundamentals Summary
| E4NA fundamental statistics | |
|---|---|
| Market cap | €73.36m |
| Earnings (TTM) | -€6.21m |
| Revenue (TTM) | €1.20m |
61.3x
P/S Ratio-11.8x
P/E RatioIs E4NA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E4NA income statement (TTM) | |
|---|---|
| Revenue | AU$1.97m |
| Cost of Revenue | AU$22.86k |
| Gross Profit | AU$1.95m |
| Other Expenses | AU$12.18m |
| Earnings | -AU$10.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0097 |
| Gross Margin | 98.84% |
| Net Profit Margin | -519.20% |
| Debt/Equity Ratio | 0% |
How did E4NA perform over the long term?
See historical performance and comparison